Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 8:24 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,507 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sequence Clear all
Active, not recruiting Not applicable Interventional

Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer

NCT03277469
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
MRI, Brachytherapy, MRI Tracker
Device · Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 3 Interventional Results available

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

NCT04492020
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant 100 mg, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 4 Interventional Results available

Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus

NCT04484259
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Coronary Artery Disease
Interventions
Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers

NCT02371603
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Nov 1, 2026, 8:24 AM EST
Terminated Phase 4 Interventional Results available

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

NCT01856023
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
High Dose Interleukin-2, Ipilimumab
Drug
Lead sponsor
Clinigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Nov 1, 2026, 8:24 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Psorcast Mobile Study

NCT05621369
View directory record Official record
Conditions
Psoriatic Arthritis, Psoriasis, Psoriatic Conditions, Dermatologic Disease, Rheumatologic Disease, Psoriatic Nail, Plaque Psoriasis, Joint Pain, Dactylitis
Interventions
Participant self-assessment surveys, Psoriasis Draw, Psoriasis Area Photo, Finger and Toe Photos, Digital Jar Open, 30 Second Walk, Psorcast mobile application
Behavioral · Other
Lead sponsor
Sage Bionetworks
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 2 Interventional Results available

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

NCT01006122
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy
Interventions
Placebo, PF-03654746
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

NCT04488016
View directory record Official record
Conditions
Bioavailability, B-cell Lymphoid Cancer
Interventions
Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993

NCT06508762
View directory record Official record
Conditions
Pain
Interventions
VX-993
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Nov 1, 2026, 8:24 AM EST
Completed No phase listed Observational

The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases

NCT01423734
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Secondary Malignant Neoplasm of Liver
Interventions
magnetic resonance imaging (MRI)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Nov 1, 2026, 8:24 AM EST
Completed Not applicable Interventional Results available

Pain Outcomes Comparing Yoga Versus Structured Exercise (POYSE) Trial

NCT01797263
View directory record Official record
Conditions
Fibromyalgia
Interventions
Yoga, Structured Exercise
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects

NCT04583228
View directory record Official record
Conditions
COVID 19
Interventions
HLX71, Placebo
Drug · Other
Lead sponsor
Hengenix Biotech Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Nov 1, 2026, 8:24 AM EST
Active, not recruiting Phase 1 Interventional

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

NCT00463814
View directory record Official record
Conditions
Tumor, Cancer
Interventions
AZD6244
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin

NCT01959399
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of ASP015K
Interventions
ASP015K, Rosuvastatin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980

NCT01473316
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0980, Ketoconazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

NCT06691828
View directory record Official record
Conditions
Healthy Volunteer
Interventions
NX-5948
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

NCT03792971
View directory record Official record
Conditions
Healthy
Interventions
Dextromethorphan HBr, GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Loperamide Grapefruit Juice Interaction PK Trial

NCT00806299
View directory record Official record
Conditions
Drug Interaction
Interventions
Loperamide / Red Grapefruit Juice, Loperamide/ White Grapefruit Juice, Loperamide / Pink Grapefruit Juice
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years to 59 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 6, 2011 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects

NCT01220232
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Abacavir/Lamivudine, Lersivirine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 4, 2011 · Synced Nov 1, 2026, 8:24 AM EST
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Preventing Loss of Independence Through Exercise in Community Living Centers

NCT06972004
View directory record Official record
Conditions
Dementia, Cognitive Dysfunction
Interventions
Preventing Loss of Independence through Exercise (PLIE)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 1, 2026, 8:24 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function

NCT05008549
View directory record Official record
Conditions
Attention, Mood
Interventions
Cranberry Juice Product
Dietary Supplement
Lead sponsor
Ocean Spray Cranberries, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Nov 1, 2026, 8:24 AM EST
Recruiting Phase 1Phase 2 Interventional

Tebentafusp-tebn With LDT in Metastatic UM

NCT06626516
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 1, 2026, 8:24 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of APX001 High-load and Low-load Tablets

NCT05491733
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
APX001, APX001A
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Nov 1, 2026, 8:24 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Using Yoga to Reduce Chaos and Improve Preschooler Sleep

NCT06549868
View directory record Official record
Conditions
Sleep, Inadequate, Sleep
Interventions
Yoga-based bedtime routine
Behavioral
Lead sponsor
Emily Guseman
Other
Eligibility
2 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Nov 1, 2026, 8:24 AM EST